Freeflow Ventures Raises $50M for Science-Driven Solutions

Freeflow Ventures, an early stage venture capital firm, has successfully raised $50 million in new funds through its $35 million Fund Two and $15 million Opportunity Fund. With assets under management now totaling $90 million.

Freeflow's most recent investment is in Catena Bio, marking its entry into the Berkeley ecosystem of deep tech startups. The firm has made over 30 investments since 2020 into companies founded by leading scientists, including Nobel Laureates Frances Arnold, David Baltimore, and Bob Grubbs. This expansion to Berkeley aligns with Freeflow's focused thesis on human and planetary health, as it aims to capitalize on the deep tech innovation and breakthrough science in both Caltech and Berkeley.

Catena Bio is a pioneer in next generation Antibody Drug Conjugate (ADC) technology, with capabilities for cancer treatment that can significantly improve patient outcomes. The firm's funding will enable it to broaden its model to Berkeley, mirroring its success at Caltech and JPL, and continuing to capitalize on high-quality investment opportunities in communities that align with its focused thesis on human and planetary health.